Agrochemicals company Astec Lifesciences announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Consolidated total income in Q2FY25 was Rs 100.5 crore as compared to Rs 111.8 crore in Q2FY24. Consolidated EBITDA loss was Rs 17.7 crore in Q2FY25 as compared to loss of Rs 2.4 crore in Q2FY24. H1FY25 Financial Highlights: In H1FY25, company reported consolidated total income of Rs 170.8 crore as compared to Rs 256.3 crore in H1FY24. In H1FY25, company reported consolidated EBITDA loss of Rs 63.1 crore as compared to profit of Rs 2.4 crore in H1FY24. N B Godrej, Chairman, Astec LifeSciences, said: In Q2FY25, Astec experienced a modest improvement in volumes within the Enterprise portfolio as compared to Q2FY24, but this positive impact was offset by lower realizations in key Enterprise products due to Chinese overcapacity and inventory destocking. This adversely impacted topline and profitability. In addition, a cautious approach adopted by CDMO customersfurther exacerbated the decline in our topline and profitability compared to Q2FY24. Result PDF